JPWO2020160468A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020160468A5 JPWO2020160468A5 JP2021544752A JP2021544752A JPWO2020160468A5 JP WO2020160468 A5 JPWO2020160468 A5 JP WO2020160468A5 JP 2021544752 A JP2021544752 A JP 2021544752A JP 2021544752 A JP2021544752 A JP 2021544752A JP WO2020160468 A5 JPWO2020160468 A5 JP WO2020160468A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- optionally
- hla
- pharmaceutical composition
- ncd
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024231447A JP2025062601A (ja) | 2019-02-01 | 2024-12-27 | 神経認知障害を処置するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962800177P | 2019-02-01 | 2019-02-01 | |
| US62/800,177 | 2019-02-01 | ||
| PCT/US2020/016206 WO2020160468A1 (en) | 2019-02-01 | 2020-01-31 | Compositions and methods for treating neurocognitive disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024231447A Division JP2025062601A (ja) | 2019-02-01 | 2024-12-27 | 神経認知障害を処置するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022523514A JP2022523514A (ja) | 2022-04-25 |
| JP2022523514A5 JP2022523514A5 (https=) | 2023-04-27 |
| JPWO2020160468A5 true JPWO2020160468A5 (https=) | 2023-04-27 |
Family
ID=71840202
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021544752A Pending JP2022523514A (ja) | 2019-02-01 | 2020-01-31 | 神経認知障害を処置するための組成物及び方法 |
| JP2024231447A Pending JP2025062601A (ja) | 2019-02-01 | 2024-12-27 | 神経認知障害を処置するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024231447A Pending JP2025062601A (ja) | 2019-02-01 | 2024-12-27 | 神経認知障害を処置するための組成物及び方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220133808A1 (https=) |
| EP (1) | EP3917620A4 (https=) |
| JP (2) | JP2022523514A (https=) |
| CA (1) | CA3127808A1 (https=) |
| IL (1) | IL285270A (https=) |
| MA (1) | MA54880A (https=) |
| WO (1) | WO2020160468A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190248A1 (ar) | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| CN112204050B (zh) | 2018-01-31 | 2025-03-14 | 艾莱克特有限责任公司 | 抗ms4a6a抗体及其使用方法 |
| CN111971301B (zh) | 2018-01-31 | 2025-01-07 | 艾莱克特有限责任公司 | 抗ms4a4a抗体及其使用方法 |
| EP4037696A4 (en) * | 2019-10-01 | 2024-02-07 | Children's Medical Center Corporation | Compositions and methods for treating alzheimer's disease |
| EP4146797A1 (en) * | 2020-05-06 | 2023-03-15 | Orchard Therapeutics (Europe) Limited | Treatment for neurodegenerative diseases |
| US20230322897A1 (en) * | 2020-07-02 | 2023-10-12 | Avrobio, Inc. | Compositions and methods for treating neurocognitive disorders |
| US20230265456A1 (en) * | 2020-08-10 | 2023-08-24 | Fundacion Para La Investigacion Medica Aplicada | Gene therapy vector expressing cyp27a1 for the treatment of cerebrotendinous xanthomatosis |
| US20220127347A1 (en) * | 2020-10-26 | 2022-04-28 | The Regents Of The University Of California | Inhibition of Tau Propagation |
| JP2024516548A (ja) | 2021-04-08 | 2024-04-16 | ジョスリン ダイアビーティス センター インコーポレイテッド | 腎機能低下の診断及び予測の方法 |
| AU2022441199A1 (en) * | 2021-09-27 | 2024-05-16 | Curelab Oncology, Inc. | Prevention and treatment of diseases by modulating activity of mesenchymal stem cells with p62 (sqstm1)-encoding vector and pharmaceutical formulations containing p62 (sqstm1) proteins |
| US20250051391A1 (en) * | 2021-12-15 | 2025-02-13 | The Governing Council Of The University Of Toronto | Peptide inhibitors and methods for inhibiting protein aggregation in neurons and neurodegenerative diseases |
| WO2024178386A1 (en) * | 2023-02-24 | 2024-08-29 | Aarhus Universitet | Methods of treating endosomal trafficking diseases |
| WO2025064926A1 (en) * | 2023-09-22 | 2025-03-27 | The Board Of Regents Of The University Of Texas System | Novel secretory signal peptides and uses thereof |
| CN117736321A (zh) * | 2023-12-20 | 2024-03-22 | 中国人民解放军空军军医大学 | 一种乙酰化修饰的特异性抗体及其应用 |
| WO2025186293A1 (en) * | 2024-03-06 | 2025-09-12 | Institut National de la Santé et de la Recherche Médicale | Chmp2b mutants for use for treating infection |
| KR20260001543A (ko) * | 2024-06-25 | 2026-01-06 | 연세대학교 산학협력단 | 바이러스 벡터를 포함한 난청 치료용 조성물 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4869399A (en) * | 1998-07-10 | 2000-02-01 | Curagen Corporation | Interaction of human beta amyloid precursor protein (beta-app) with human lon-protease like protein (hslon) |
| US20050163760A1 (en) * | 2001-12-06 | 2005-07-28 | Nathalie Cartier-Lacave | Use of cd34+ hematopoietic progenitor cells for the treatment of cns disorders |
| US20130102538A1 (en) * | 2010-05-05 | 2013-04-25 | Amicus Therapeutics, Inc. | Method of treating alzheimer's disease using pharmacological chaperones to increase presenilin function and gamma-secretase activity |
| JP2016537995A (ja) * | 2013-11-05 | 2016-12-08 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 新しいアルツハイマー病動物モデル |
| US11066456B2 (en) * | 2016-02-25 | 2021-07-20 | Washington University | Compositions comprising TREM2 and methods of use thereof |
| JOP20190248A1 (ar) * | 2017-04-21 | 2019-10-20 | Amgen Inc | بروتينات ربط مولد ضد trem2 واستخداماته |
| KR102040364B1 (ko) * | 2017-05-26 | 2019-11-05 | 가천대학교 산학협력단 | 알츠하이머병 관련 ３０개 유전자를 이용한 유전적 진단방법 |
| KR20200032722A (ko) * | 2017-07-27 | 2020-03-26 | 노파르티스 아게 | 부분절단효소 내성 trem2 변이체 |
-
2020
- 2020-01-31 MA MA054880A patent/MA54880A/fr unknown
- 2020-01-31 EP EP20749692.8A patent/EP3917620A4/en active Pending
- 2020-01-31 JP JP2021544752A patent/JP2022523514A/ja active Pending
- 2020-01-31 US US17/427,252 patent/US20220133808A1/en active Pending
- 2020-01-31 CA CA3127808A patent/CA3127808A1/en active Pending
- 2020-01-31 WO PCT/US2020/016206 patent/WO2020160468A1/en not_active Ceased
-
2021
- 2021-08-01 IL IL285270A patent/IL285270A/en unknown
-
2024
- 2024-12-27 JP JP2024231447A patent/JP2025062601A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11965174B2 (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| US20230295659A1 (en) | TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs) | |
| JPWO2020160468A5 (https=) | ||
| Dashkoff et al. | Tailored transgene expression to specific cell types in the central nervous system after peripheral injection with AAV9 | |
| JP2025015673A (ja) | 脊髄軟膜下遺伝子送達システム | |
| JPWO2020160458A5 (https=) | ||
| Iida et al. | Systemic delivery of tyrosine‐mutant AAV vectors results in robust transduction of neurons in adult mice | |
| US8278428B2 (en) | Mitochondrial nucleic acid delivery systems | |
| US20230190893A1 (en) | Compositions and methods for treating an inherited retinal disease | |
| Hoshino et al. | The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury | |
| JP2024123093A (ja) | 筋萎縮性側索硬化症の治療におけるコレステロール２４―ヒドロラーゼの発現ベクター | |
| Chatterjee et al. | Adeno-associated virus and hematopoietic stem cells: the potential of adeno-associated virus hematopoietic stem cells in genetic medicines | |
| JP2021526839A (ja) | 眼圧及び頭蓋内圧を調節するための材料及び方法 | |
| JPWO2019173756A5 (https=) | ||
| JPWO2020160441A5 (https=) | ||
| Hirai et al. | Blood–brain barrier-penetrant AAV vectors for cell type-specific gene expression in the mouse brain: H. Hirai et al. | |
| US20240156873A1 (en) | Methods to genetically engineer hematopoietic stem and progenitor cells for red cell specific expression of therapeutic proteins | |
| Leblay et al. | From Gene to Hope: Rett Syndrome and the Rise of Molecular Therapies | |
| WO2024226729A2 (en) | Compositions and methods for opa1 gene therapy | |
| JP2024542015A (ja) | 脳内でのｔｃｆ７ｌ２媒介性髄鞘再生 | |
| HK40049414A (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| Seymour et al. | European Society of Gene and Cell Therapy British Society for Gene Therapy Collaborative Congress 2011 October 27–31, 2011 The Brighton Centre, Brighton United Kingdom | |
| Kojima et al. | The adeno-associated virus rh10 vector is an effective gene transfer system for chronic spinal cord injury | |
| HK1240977A1 (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof | |
| HK1240977B (en) | Adeno-associated virus vector variants for high efficiency genome editing and methods thereof |